Lexicon Pharma (LXRX) Tops Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500, Nasdaq rise as tech stocks gain ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mail
Get Alerts LXRX Hot Sheet
Price: $1.47 +2.08%
EPS Growth %: -50.0%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
INM, TRI, CRVL, More
EPS Growth %: -50.0%
Financial Fact:
Total revenues: 27.72M
Today's EPS Names:
INM, TRI, CRVL, More
Join SI Premium – FREE
Lexicon Pharma (NASDAQ: LXRX) reported Q2 EPS of ($0.13), $0.03 better than the analyst estimate of ($0.16). Revenue for the quarter came in at $234 thousand, versus $9.16 million reported last year.
For earnings history and earnings-related data on Lexicon Pharma (LXRX) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Yorkville Ives names top software pick for 2027: Microsoft leads on AI strengthÂ
- Syra Health Corp. (SYRA) Reports Q3 EPS of $0.02
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
